Vaccine biotechnology company Novavax NASDAQ:NVAX announced better-than-expected revenue in Q2 CY2026, but sales fell by 76.3% year on year to $56.7 million. Its GAAP loss of $0.32 per share was 16.6% above analysts’ consensus estimates.Novavax (NVAX) Q2 CY2026 Highlights:"We're encouraged by the m…
Novavax reported second-quarter 2026 total revenue of $57.0 million and a net loss of $53.4 million, reflecting a decline from the prior-year period that included sizable milestone-related revenue. The company improved its full-year 2026 Combined R&D and SG&A expense guidance by $10 million at the…
NOVAVAX INC reported second-quarter 2026 results showing a sharp year-over-year decline in revenue and a return to a net loss for the quarter, driven by fewer one-time milestone and agreement-related items versus the prior-year period.Financial Highlights¹ Reported as “Total revenue”. ² Reported as…
Vaccine biotechnology company Novavax NASDAQ:NVAX will be reporting results this Thursday before the bell. Here’s what you need to know.Novavax beat analysts’ revenue expectations last quarter, reporting revenues of $139.5 million, down 79.1% year on year. It was an incredible quarter for the compa…
